Health Care [ 11/12 ] | Biotechnology [ 66/75 ]
NASDAQ | Common Stock
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.
The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia.
The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules.
In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera.
Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jul 31, 24 | -0.08 Decreased by -366.67% | -0.21 Increased by +61.90% |
| May 8, 24 | -0.07 Decreased by -219.67% | 0.05 Decreased by -243.60% |
| Feb 7, 24 | -0.04 Decreased by -133.33% | -0.09 Increased by +55.56% |
| Nov 8, 23 | 0.00 Decreased by -96.00% | -0.04 Increased by +106.00% |
| Jul 27, 23 | 0.03 Decreased by -40.00% | -0.13 Increased by +123.08% |
| May 3, 23 | 0.06 Increased by +154.55% | - |
| Feb 8, 23 | 0.12 Increased by 0.00% | 0.08 Increased by +50.00% |
| Nov 2, 22 | 0.06 Decreased by -57.14% | 0.09 Decreased by -33.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 47.46 M Decreased by -24.06% | -4.15 M Decreased by -227.49% | Decreased by -8.74% Decreased by -267.88% |
| Dec 31, 23 | 45.27 M Decreased by -29.79% | -2.40 M Decreased by -134.98% | Decreased by -5.30% Decreased by -149.82% |
| Sep 30, 23 | 38.81 M Decreased by -40.58% | 137.00 K Decreased by -95.81% | Increased by +0.35% Decreased by -92.95% |
| Jun 30, 23 | 46.06 M Decreased by -28.47% | 1.52 M Decreased by -40.95% | Increased by +3.30% Decreased by -17.44% |
| Mar 31, 23 | 62.50 M Increased by +3.83% | 3.25 M Increased by +150.58% | Increased by +5.20% Increased by +148.71% |
| Dec 31, 22 | 64.48 M Decreased by -5.20% | 6.86 M Decreased by -3.07% | Increased by +10.64% Increased by +2.25% |
| Sep 30, 22 | 65.32 M Decreased by -6.82% | 3.27 M Decreased by -57.92% | Increased by +5.01% Decreased by -54.84% |
| Jun 30, 22 | 64.39 M Decreased by -5.17% | 2.57 M Decreased by -73.33% | Increased by +4.00% Decreased by -71.88% |